Join our daily newsletter At The Bell to receive exclusive market insights
- Little Green Pharma (LGP) secures its registration for locally produced cannabis medicine in Denmark by the Danish Medicines Agency
- The 16 per cent THC ‘Billinol LGP’ will be sold in five gram pouches for roughly $32 per gram
- The grant represents the culmination of a two-and-a-half-year application progress, with Billinol being the first locally produced cannabis medicine in Denmark to receive the registration
- The medicine will be cultivated and produced at Little Green Pharma’s Denmark facility, and is hoped to be distributed to patients before the end of the year
- Little Green Pharma was down 0.75 per cent to $0.66 per share at the close of trading on Tuesday
Little Green Pharma (LGP) has secured its registration for locally produced cannabis medicine in Denmark.
The company was granted approval for its 16 per cent THC ‘Billinol LGP’ cannabis flower medicine by the Danish Medicines Agency.
Billinol LGP will be sold in five-gram alubag pouches for roughly $32 per gram.
The grant represents the culmination of a two-and-a-half-year application progress, with Billinol being the first locally produced cannabis medicine in Denmark to receive the registration.
The medicine will be cultivated and produced at Little Green Pharma’s Denmark facility.
LGP said the registration aligns with its strategy of being first to market in key territories, enabling it to rapidly build a brand reputation for quality products and services with new market participants.
LGP has previously employed this same strategy in Australia and France, and — following Denmark — expects to repeat it in Poland in the future.
The group said it expects to distribute its first products to patients before the end of the year.
Little Green Pharma was down 0.75 per cent to $0.66 per share at the close of trading on Tuesday.
